이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

진행성 유방암을 앓고 있는 일본 남성 및 폐경 후 여성에서 알펠리십 플러스 풀베스트란트 치료의 효능 및 안전성을 평가하는 연구

2026년 9월 17일 업데이트: Novartis Pharmaceuticals

PIK3CA 돌연변이 호르몬 수용체(HR) 양성, HER2 음성, 진행성 유방암을 앓고 있는 남성 및 폐경 후 여성을 대상으로 풀베스트란트와 병용한 BYL719(알펠리십)의 II상 공개 라벨, 2부분, 다기관 연구 일본에서 Aromatase Inhibitor(AI) 치료 후

The purpose of this study is to assess the safety and efficacy of alpelisib plus fulvestrant in men and postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor 2 (HER2)-negative, advanced breast cancer harboring a PIK3CA mutation in Japan, whose disease has progressed on or after aromatase inhibitor (AI) treatment regardless of prior CDK4/6 inhibitor use.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

This is a Phase II open-label, 2-Part, multi-center study in Japan. The study will be conducted in two parts: Part 1 (Cohort 1) includes participants regardless of prior CDK4/6 inhibitor use and is designed to determine the recommended dose (RD), evaluate the tolerability and safety of alpelisib in combination with fulvestrant. Part 2 consists of 2 cohorts (the CDK4/6 inhibitor naive participants are in Cohort 2 and the CDK4/6 inhibitor pre-treated participants are in Cohort 3) which are designed to assess the efficacy and safety of alpelisib in combination with fulvestrant, will start once the RD of alpelisib is established.

Participants will be treated until disease progression, unacceptable toxicity, death or discontinuation from the study treatment for any other reason and will be followed for survival regardless of treatment discontinuation reason (except if consent is withdrawn or participant is lost to follow up).

연구 유형

중재적

등록 (실제)

24

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Niigata, 일본, 951-8566
        • Novartis Investigative Site
    • Aichi-ken
      • Nagoya, Aichi-ken, 일본, 4668560
        • Novartis Investigative Site
      • Nagoya, Aichi-ken, 일본, 4678602
        • Novartis Investigative Site
      • Nagoya, Aichi-ken, 일본, 4648681
        • Novartis Investigative Site
    • Chiba
      • Kashiwa, Chiba, 일본, 2778577
        • Novartis Investigative Site
    • Kanagawa
      • Isehara, Kanagawa, 일본, 2591193
        • Novartis Investigative Site
      • Yokohama, Kanagawa, 일본, 2418515
        • Novartis Investigative Site
    • Kumamoto
      • Kumamoto, Kumamoto, 일본, 8608556
        • Novartis Investigative Site
    • Miyagi
      • Sendai, Miyagi, 일본, 9808574
        • Novartis Investigative Site
    • Osaka
      • Osaka, Osaka, 일본, 5418567
        • Novartis Investigative Site
      • Osaka, Osaka, 일본, 5400006
        • Novartis Investigative Site
      • Suita, Osaka, 일본, 5650871
        • Novartis Investigative Site
    • Tokyo
      • Bunkyo Ku, Tokyo, 일본, 1138677
        • Novartis Investigative Site
      • Koto Ku, Tokyo, 일본, 1358550
        • Novartis Investigative Site
      • Meguro-ku, Tokyo, 일본, 1528902
        • Novartis Investigative Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Japanese man or postmenopausal woman
  • Participant has adequate tumor tissue for the analysis of PIK3CA mutational status by a Novartis designated laboratory.
  • Participant has identified PIK3CA mutation (as determined by a Novartis designated laboratory)
  • Participant has a histologically and/or cytologically confirmed diagnosis of ER+ and/or PgR+ breast cancer by local laboratory
  • Participant has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH or SISH) test is required by local laboratory testing
  • Participant has measurable disease, i.e., at least one measurable lesion as per RECIST 1.1
  • Participant has advanced breast cancer
  • Participant has ECOG performance status 0 or 1

Exclusion Criteria:

  • Participant with symptomatic visceral disease or any disease burden that makes the participant ineligible for endocrine therapy per the investigator's best judgment
  • Participant has received prior treatment;
  • with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, any PI3K, mTOR or AKT inhibitor for Cohort 1 and 3
  • with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, any PI3K, mTOR, AKT inhibitor or CDK 4/6 inhibitor for Cohort 2
  • Participant has a known hypersensitivity to alpelisib or fulvestrant, or to any of the excipients of alpelisib or fulvestrant
  • Participant with inflammatory breast cancer at screening
  • Participant is concurrently using other anti-cancer therapy
  • Participant has had surgery within 14 days prior to starting study drug or has not recovered from major side effects
  • Participant with an established diagnosis at screening of diabetes mellitus type I or not controlled type II (based on FPG and HbA1c)
  • Participant has currently documented pneumonitis /interstitial lung disease
  • History of acute pancreatitis within 1 year of screening or past medical history of chronic pancreatitis
  • Participant with unresolved osteonecrosis of the jaw
  • Participant has a history of severe cutaneous reactions

Other protocol-defined inclusion/exclusion criteria may apply

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Cohort 1:CDK4/6 inhibitor naive or pre-treated (Part 1)

Participants regardless of prior CDK4/6 inhibitor will be treated at escalating doses (200 mg, 250 mg and 300 mg, orally) of BYL719 in combination with Fulvestrant (500 mg, intramuscular).

[Part 1] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.

If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated.

[Part 2] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1.

다른 이름들:
  • 바일719

Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).

다른 이름들:
  • 파슬로덱스
실험적: Cohort 2: CDK4/6 inhibitor naive (Part 2)

Participants who are CDK4/6 inhibitor naive will be treated with BYL719 at the recommended dose identified in Part 1 in combination with Fulvestrant (500 mg, intramuscular).

[Part 1] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.

If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated.

[Part 2] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1.

다른 이름들:
  • 바일719

Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).

다른 이름들:
  • 파슬로덱스
실험적: Cohort 3: CDK4/6 inhibitor pre-treated (Part 2)

Participants who are CDK4/6 inhibitor pre-treated will be treated with BYL719 at the recommended dose identified in Part 1 in combination with Fulvestrant (500 mg, intramuscular).

[Part 1] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.

If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated.

[Part 2] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1.

다른 이름들:
  • 바일719

Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).

다른 이름들:
  • 파슬로덱스

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
[Part 1] The incidence of Dose Limiting Toxicities (DLTs) of alpelisib in combination with fulvestrant
기간: From Cycle 1 Day 1 to Cycle 2 Day 28 (Cycle = 28 days)

A DLT is defined as an AE or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first 2 cycles (the first 56 days) of treatment with alpelisib in combination with fulvestrant and meets any of the criteria specified in the protocol .

From Cycle 1 Day 1 to Cycle 2 Day 28 (Cycle = 28 days)
[Part 2] Overall Response Rate (ORR) in CDK4/6 inhibitor naive participants
기간: Up to approximately 36 months

ORR is defined as the proportion of participants with best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on local investigator assessment per RECIST 1.1.

Up to approximately 36 months

2차 결과 측정

결과 측정
측정값 설명
기간
[Part 1] Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: Up to approximately 37 months

Safety is determined by incidence, type, and severity of adverse events per CTCAE v4.03 criteria including changes in laboratory values, vital signs, liver assessments, renal and cardiac assessments.

Up to approximately 37 months
[Part 1] Number of participants with dose adjustments
기간: Up to approximately 37 months

The number of participants with dose adjustments (reductions, interruption, or permanent discontinuation) and the reasons

Up to approximately 37 months
[Part 1] Dose intensity for alpelisib and fulvestrant
기간: Up to approximately 37 months

The dose intensity (computed as the ratio of actual cumulative dose received and actual duration of exposure) and the relative dose intensity (computed as the ratio of dose intensity and planned dose intensity)

Up to approximately 37 months
[Part 1] Duration of exposure for alpelisib and fulvestrant
기간: Up to approximately 37 months

The duration of exposure (in months) to alpelisib and fulvestrant

Up to approximately 37 months
[Part 1] Plasma concentrations of alpelisib in combination with fulvestrant
기간: Cycle 1 Day 8 (pre-dose), 15 (pre-dose, post-dose 1 hour, 3 hours) and Day 1 of Cycles 2, 4, 6, 8 (pre-dose) (Cycle = 28 days)

Summary statistics of alpelisib plasma concentrations by time point and dose level

Cycle 1 Day 8 (pre-dose), 15 (pre-dose, post-dose 1 hour, 3 hours) and Day 1 of Cycles 2, 4, 6, 8 (pre-dose) (Cycle = 28 days)
[Part 2] Overall Response Rate (ORR) for CDK4/6 inhibitor pre-treated participants
기간: Up to approximately 36 months

ORR is defined as the proportion of participants with best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on local investigator assessment per RECIST 1.1.

Up to approximately 36 months
[Part 2] Progression Free Survival (PFS)
기간: Up to approximately 36 months

PFS is defined as the time from the date of first administration of study treatment until the date of the first documented progression or death due to any cause. PFS will be assessed based on local investigator assessment per RECIST 1.1.

Up to approximately 36 months
[Part 2] Overall Survival (OS)
기간: Up to approximately 60 months

OS is defined as the time from date of first administration of study treatment until date of death due to any cause.

Up to approximately 60 months
[Part 2] Clinical Benefit Rate (CBR)
기간: Up to approximately 36 months

CBR is defined as the proportion of participants with a best overall response of confirmed CR, or confirmed PR, or an overall response of confirmed stable disease (SD), lasting for a duration of at least 24 weeks. CR, PR, and SD are defined based on local investigator assessment per RECIST 1.1.

Up to approximately 36 months
[Part 2] Duration of Response (DOR)
기간: Up to approximately 36 months

DOR only applies to participants whose best overall response is CR or PR based on local investigator assessment per RECIST 1.1. The start date is the date of first documented response of CR or PR (i.e. the start date of response, not the date when response was confirmed), and the end date is defined as the date of the first documented progression or death due to underlying cancer.

Up to approximately 36 months
[Part 2] Time to Response (TTR)
기간: Up to approximately 36 months

TTR is defined as the time from the date of first administration of study treatment until the date of the first documented response of either CR or PR, which must be subsequently confirmed (although date of initial response is used, not date of confirmation).

Up to approximately 36 months
[Part 2] Time to definitive deterioration of Eastern Cooperative Oncology Group (ECOG) performance status
기간: Up to approximately 36 months

Time to definitive deterioration in ECOG performance status is defined as the time from the date of first administration to the date when ECOG performance status has definitively deteriorated by at least one category compared with baseline. Deterioration is considered definitive if there is no subsequent improvement in ECOG performance status back to the baseline category or above.

Up to approximately 36 months
[Part 2] Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: Up to approximately 37 months

Incidence, type, and severity of adverse events per CTCAE v4.03 criteria including changes in laboratory values, vital signs, liver assessments, renal and cardiac assessments

Up to approximately 37 months
[Part 2] Number of participants with dose adjustments
기간: Up to approximately 37 months

The number and percentage of participants with dose interruptions and dose reductions

Up to approximately 37 months
[Part 2] Dose intensity for alpelisib and fulvestrant
기간: Up to approximately 37 months

The dose intensity (computed as the ratio of actual cumulative dose received and actual duration of exposure) and the relative dose intensity (computed as the ratio of dose intensity and planned dose intensity)

Up to approximately 37 months
[Part 2] Duration of exposure for alpelisib and fulvestrant
기간: Up to approximately 37 months

The duration of exposure (in months) to alpelisib and fulvestrant

Up to approximately 37 months
[Part 2] Plasma concentrations of alpelisib in combination with fulvestrant
기간: Cycle 1 Day 8 (pre-dose), 15 (pre-dose, post-dose 1 hour, 3 hours) and Day 1 of Cycles 2, 4, 6, 8 (pre-dose) (Cycle= 28 days)

Summary statistics of alpelisib plasma concentrations by time point and dose level

Cycle 1 Day 8 (pre-dose), 15 (pre-dose, post-dose 1 hour, 3 hours) and Day 1 of Cycles 2, 4, 6, 8 (pre-dose) (Cycle= 28 days)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Novartis Pharmaceuticals, Novartis Pharmaceuticals

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 1월 8일

기본 완료 (추정된)

2027년 2월 26일

연구 완료 (추정된)

2027년 2월 27일

연구 등록 날짜

최초 제출

2020년 8월 19일

QC 기준을 충족하는 최초 제출

2020년 8월 19일

처음 게시됨 (실제)

2020년 8월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 17일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • CBYL719C1201

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .